Samsung Biologics Expands Global Manufacturing with GSK Facility Acquisition in Maryland
Samsung Biologics, a prominent player in the contract development and manufacturing landscape, has marked a significant milestone with the acquisition of GlaxoSmithKline's (GSK) manufacturing facility situated in Rockville, Maryland. This strategic move not only establishes Samsung Biologics' first manufacturing presence in the United States but also expands its total global manufacturing capacity to an impressive 845,000 liters.
The newly acquired Rockville site boasts two state-of-the-art cGMP manufacturing plants, which collectively hold a capacity of 60,000 liters for drug substances. This facility is designed to support both clinical and commercial biologics production, catering to a variety of manufacturing scales. Samsung intends to ensure continuity by continuing to produce GSK's products under the terms of the acquisition, while also redirecting the site's capabilities to meet additional contract manufacturing needs.
John Rim, President and CEO of Samsung Biologics, expressed enthusiasm about this acquisition. "This significant addition to our U.S. manufacturing footprint enhances our capability to operate a geographically diversified manufacturing network. Moreover, we are excited to welcome over 500 new colleagues from the Rockville team into the Samsung Biologics family, all of whom bring invaluable expertise and operational experience," Rim stated.
Samsung Biologics aims to further expand the facility's capacity and upgrade its technologies, reinforcing its long-term commitment to building a robust global supply chain and improving access to crucial medicines.
The establishment of a manufacturing presence in the U.S. strengthens Samsung Biologics' strategic position within the biopharmaceutical industry, allowing for enhanced support to regional clients and greater responsiveness to market demands. This acquisition aligns with the company's overarching mission to provide essential therapies to patients around the globe.
Samsung Biologics operates an extensive manufacturing network that spans multiple regions, including Korea and Japan, positioning itself as a leader in biomanufacturing for next-generation therapies and innovative modalities such as multispecific antibodies and mRNA therapeutics.
With the implementation of its ExellenS™ framework across its manufacturing sites, Samsung Biologics maintains high standards through standardized designs, unified processes, and advanced digitalization, ensuring efficiency and consistency in manufacturing operations.
As it looks to the future, Samsung Biologics remains dedicated to investing in the evolution of its capabilities, thereby enhancing operational excellence and delivering high-quality biomedicines to clients with precision and reliability. With the expansion into the Rockville facility, the company is poised to play a pivotal role in shaping the future of healthcare and addressing the pressing needs of patients worldwide. For those interested in learning more about Samsung Biologics and its expanding capabilities, detailed information is available on their official website.
The newly acquired Rockville site boasts two state-of-the-art cGMP manufacturing plants, which collectively hold a capacity of 60,000 liters for drug substances. This facility is designed to support both clinical and commercial biologics production, catering to a variety of manufacturing scales. Samsung intends to ensure continuity by continuing to produce GSK's products under the terms of the acquisition, while also redirecting the site's capabilities to meet additional contract manufacturing needs.
John Rim, President and CEO of Samsung Biologics, expressed enthusiasm about this acquisition. "This significant addition to our U.S. manufacturing footprint enhances our capability to operate a geographically diversified manufacturing network. Moreover, we are excited to welcome over 500 new colleagues from the Rockville team into the Samsung Biologics family, all of whom bring invaluable expertise and operational experience," Rim stated.
Samsung Biologics aims to further expand the facility's capacity and upgrade its technologies, reinforcing its long-term commitment to building a robust global supply chain and improving access to crucial medicines.
The establishment of a manufacturing presence in the U.S. strengthens Samsung Biologics' strategic position within the biopharmaceutical industry, allowing for enhanced support to regional clients and greater responsiveness to market demands. This acquisition aligns with the company's overarching mission to provide essential therapies to patients around the globe.
Samsung Biologics operates an extensive manufacturing network that spans multiple regions, including Korea and Japan, positioning itself as a leader in biomanufacturing for next-generation therapies and innovative modalities such as multispecific antibodies and mRNA therapeutics.
With the implementation of its ExellenS™ framework across its manufacturing sites, Samsung Biologics maintains high standards through standardized designs, unified processes, and advanced digitalization, ensuring efficiency and consistency in manufacturing operations.
As it looks to the future, Samsung Biologics remains dedicated to investing in the evolution of its capabilities, thereby enhancing operational excellence and delivering high-quality biomedicines to clients with precision and reliability. With the expansion into the Rockville facility, the company is poised to play a pivotal role in shaping the future of healthcare and addressing the pressing needs of patients worldwide. For those interested in learning more about Samsung Biologics and its expanding capabilities, detailed information is available on their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.